BML Capital Management LLC Acquires 30,000 Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

BML Capital Management LLC increased its holdings in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 20.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 180,000 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Verrica Pharmaceuticals makes up 1.0% of BML Capital Management LLC’s holdings, making the stock its 18th biggest holding. BML Capital Management LLC’s holdings in Verrica Pharmaceuticals were worth $1,318,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Jump Financial LLC bought a new stake in shares of Verrica Pharmaceuticals during the 3rd quarter worth $71,000. Kovitz Investment Group Partners LLC increased its holdings in Verrica Pharmaceuticals by 44.3% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 50,125 shares of the company’s stock worth $195,000 after purchasing an additional 15,400 shares in the last quarter. Finally, FMR LLC increased its holdings in Verrica Pharmaceuticals by 29.4% in the 3rd quarter. FMR LLC now owns 1,504,716 shares of the company’s stock worth $5,846,000 after purchasing an additional 341,584 shares in the last quarter. 42.45% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. HC Wainwright upped their target price on Verrica Pharmaceuticals from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Verrica Pharmaceuticals in a report on Wednesday, April 10th.

Verrica Pharmaceuticals Trading Up 0.9 %

Shares of VRCA stock opened at $6.85 on Wednesday. The stock has a 50-day moving average of $5.72 and a 200-day moving average of $5.09. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.55 and a quick ratio of 4.49. Verrica Pharmaceuticals Inc. has a 1-year low of $2.86 and a 1-year high of $7.76.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $1.99 million during the quarter, compared to analyst estimates of $1.10 million. Verrica Pharmaceuticals had a negative net margin of 1,307.47% and a negative return on equity of 119.46%. As a group, analysts expect that Verrica Pharmaceuticals Inc. will post -1.59 earnings per share for the current year.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.